NCT03316573 2026-02-10Pembrolizumab in Neoplasms or LymphomasDana-Farber Cancer InstitutePhase 2 Suspended18 enrolled 16 charts
NCT03674411 2026-01-06Trial Evaluating MGTA-456 in Patients With High-Risk MalignancyMasonic Cancer Center, University of MinnesotaPhase 2 Active not recruiting22 enrolled 19 charts